Xcout IntelKodiak Sciences Inc
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Subscribe to see Kodiak Sciences Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Kodiak Sciences Inc at a glance
Kodiak Sciences Inc is a biotech company headquartered in Palo Alto, United States. It is publicly listed (KOD) with a market capitalisation of $5.9B. Xcout tracks 16 named people at Kodiak Sciences Inc, including John A. Borgeson (Executive Vice President, Chief Financial Officer & Secretary). Xcout recorded 170 job postings from Kodiak Sciences Inc in the last 90 days.
Kodiak Sciences Inc leadership
- John A. BorgesonExecutive Vice President, Chief Financial Officer & Secretary
- Wayne ToChief Technology Officer
- Almas QudratChief Quality Officer
- Dolly S. ChangChief Scientific Officer
- J. Pablo Velazquez-MartinChief Medical Officer
- Victor PerlrothCo-Founder, Chairman, Chief Executive Officer & President
10 more named people on record for Kodiak Sciences Inc, with roles, board committees and tenure — see the full roster →
Kodiak Sciences Inc funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $34M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Kodiak Sciences Inc
Xcout recorded 170 job postings from Kodiak Sciences Inc in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Kodiak Sciences Inc's hiring signals →
Hiring vs the trend
Based on 72 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Kodiak Sciences Inc’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
Get Kodiak Sciences Inc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Kodiak Sciences Inc in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access